Morphosys’ ($MOR) patent trial against Janssen ($JNJ) and Genmab was headed for trial in February. In advance of that trial, however, the parties traded numerous summary judgment motions. On January 26, Genmab announced that the District Court granted its motion to invalidate the asserted patents. What happens next?
Read MoreEarlier this week, we blogged about the series of pending summary judgment motions in MorphoSys’ ($MOR) lawsuit accusing Janssen’s ($JNJ) Darzalex® of infringing its patents. The Court heard oral argument on December 3. The transcript of that hearing is not currently publicly available. The Court, however, did issue oral rulings at the end of the hearing that hit the docket on December 4. What do the rulings mean?
Read More